ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Clinical vulnerability to chemotherapy in cholangiocarcinoma: impact of nutritional status, frailty, and systemic inflammation.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo determine the contribution of frailty, nutritional status, and systemic inflammation to early toxicity and treatment modifications in patients with advanced cholangiocarcinoma (CCA) treated with gemcitabine-cisplatin plus immune checkpoint inhibitors (ICIs).
methodsPatients with unresectable or metastatic CCA who received first-line gemcitabine-cisplatin plus durvalumab or pembrolizumab were retrospectively analyzed. Frailty, nutritional status, and systemic inflammation were assessed using the five-item modified frailty index (mFI-5), prognostic nutritional index (PNI), and neutrophil-to-lymphocyte ratio (NLR). The primary outcome was suboptimal relative dose intensity (RDI < 75%) during the first six weeks of treatment. Secondary outcomes included grade ≥ 3 adverse events (AEs) and overall survival (OS).
resultsFifty-four patients were included. Univariable analyses indicated that lower PNI, hypoalbuminemia, older age, poorer performance status, and initial dose reduction were associated with suboptimal RDI. Lower PNI was independently associated with an increased risk of grade ≥ 3 AEs (adjusted odds ratio, 0.81; 95% confidence interval, 0.69-0.93). Patients with grade ≥ 3 AEs had significantly lower PNI and serum albumin levels; mFI-5, NLR, age, and performance status did not differ significantly between groups. In survival analyses, low PNI (< 42.9) was associated with significantly worse OS (log-rank p = 0.0036). An elevated NLR (≥ 3) was associated with OS; its prognostic impact was limited, whereas mFI-5 ≥ 2 was not. Performance status remained the strongest independent predictor of OS in multivariable models.
conclusionsAmong the evaluated vulnerability measures, PNI appeared to be an important marker associated with early treatment-related toxicity and survival in patients with advanced CCA treated with gemcitabine-cisplatin plus ICIs.
Indexed as
Identifiers
42303816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.